Wedbush Reiterates “Outperform” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush’s price target suggests a potential upside of 132.56% from the company’s current price.

A number of other analysts also recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX traded up $0.04 during trading on Monday, reaching $3.01. The company had a trading volume of 281,392 shares, compared to its average volume of 266,621. TScan Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $160.65 million, a P/E ratio of -2.84 and a beta of 0.79. The company has a fifty day moving average of $4.57 and a two-hundred day moving average of $5.64.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.86 million. Equities research analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Great Point Partners LLC bought a new position in shares of TScan Therapeutics during the second quarter valued at about $5,504,000. Checkpoint Capital L.P. purchased a new position in TScan Therapeutics during the 3rd quarter valued at about $4,110,000. State Street Corp raised its position in TScan Therapeutics by 24.4% during the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares during the last quarter. Bank of Montreal Can purchased a new stake in TScan Therapeutics in the 2nd quarter worth approximately $749,000. Finally, Bank of New York Mellon Corp purchased a new stake in TScan Therapeutics in the 2nd quarter worth approximately $682,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.